All In MedTech

FDA Clearance Tracker · P930036-S021

Atellica IM Alpha Fetoprotein (AFP)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 8, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P930036-S021
Device name
Atellica IM Alpha Fetoprotein (AFP)
Applicant location
East Walpole, MA
Received
Aug 14, 2023
Decided
Feb 8, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P930036

Device type

Device class
Class III

Every decision under product code LOK

FDA's approval statement

As written in FDA's record.

migration of the ADVIA Centaur AFP assay to the Atellica CI Analyzer

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.